This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
What Lies Ahead for Pharma ETFs in Second Half 2017
by Zacks Equity Research
We discuss some of the factors that could contribute to a sustained recovery in the sector.
Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus
by Zacks Equity Research
Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.
Trumpcare Collapse Fuels Rally in Healthcare Stocks & ETFs
by Sweta Killa
With the failure of Trumpcare, the healthcare sector looks more stable.
Should You Buy Pharma ETFs Now?
by Zacks Equity Research
After a challenging 2016, are Pharma ETFs poised to rebound this year?
What Lies Ahead for Pharma ETFs?
by Zacks Equity Research
Pharma ETFs have sold off after Trump's comments; can they rebound?
Will a Clinton Presidency Spell Doom for Pharma ETFs?
by Zacks Equity Research
Ongoing drug pricing controversy continues to weigh on the industry but there are several reasons to take a look at the beaten down ETFs.